Feasibility, Acceptability, and Protective Efficacy of Seasonal Malaria Chemoprevention Implementation in Nampula Province, Mozambique: Protocol for a Hybrid Effectiveness-Implementation Study

• DOI: 10.2196/36403
• Publication Date: 2022-07-30T19:51:35Z
• Authors: Kevin Baker; Pedro Aide; Craig A Bonnington; Christian Rassi; Sol Richardson; Arantxa Roca-Feltrer; Maria Rodrigues; Mercia Sitoe; Ivan Alejandro Pu...; Sonia Enosse; Caitlin McGugan; Eva Amelia de Car...; Francisco Saute; Alfredo Gabriel M...; Baltazar Candrinho
• Keywords: Amodiaquine

Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent infections in areas where the burden high and transmission occurs mainly during rainy season. In Africa, so far, SMC has been implemented Sahel region. Mozambique contributes 4% of global cases, responsible for one-quarter all deaths country. Based on recommendations Malaria Strategic Plan, Consortium, partnership with National Control Programme Mozambique, initiated phased implementation study northern province Nampula. The first phase this 2-year was conducted 2020-2021 focused feasibility acceptability SMC. second will focus demonstrating impact. This paper describes 2 study.Specific objectives include following: (1) determine effectiveness terms its reduction incidence infection among children aged 3 59 months; (2) efficacy sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) when used Nampula Province, extent which impacted by drug resistance concentrations; (3) investigate presence change SP+AQ- piperaquine-resistance markers over time as result implementation; (4) understand impact model, determining process outcomes intervention.This type 2, hybrid, effectiveness-implementation uses convergent mixed methods approach. be four monthly cycles between December 2021 March 2022 districts Province. Phase components: cluster randomized controlled trial establish confirmed prospective cohort antimalarials whether concentrations or influence duration protection, marker months describe changes prevalence time, evaluation SMC.Data collection began mid-January 2022, data analysis expected completed October 2022.This Mozambique. findings from crucial policy program expansion other suitable geographies outside Sahel. unique opportunity better new environment.ClinicalTrials.gov NCT05186363; https://clinicaltrials.gov/ct2/show/NCT05186363.DERR1-10.2196/36403.